Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic γδ T Cells for MRD-positive AML Post-Allo-HSCT
NCT07126782Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of allogeneic gamma-delta T cells in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Objective Response Rate at 4 weeks. Started Jul 2025; status: recruiting.
02
Drugs
allogeneic gamma-delta T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07126782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07126782.